Trexquant Investment’s Aclaris Therapeutics ACRS Stock Holding History

Trexquant Investment’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-127,851	Closed	-$876K	–	1375
2023 Q3	$876K	Buy	+127,851	New	+$1.09M	0.02%	799
2022 Q1	–	Sell	-14,587	Closed	-$212K	–	1297
2021 Q4	$212K	Buy	+14,587	New	+$221K	0.01%	1118
2021 Q3	–	Sell	-13,555	Closed	-$238K	–	1087
2021 Q2	$238K	Buy	+13,555	New	+$308K	0.02%	824
2018 Q2	–	Sell	-20,222	Closed	-$354K	–	860
2018 Q1	$354K	Buy	+20,222	New	+$429K	0.02%	756
2017 Q4	–	Sell	-9,579	Closed	-$247K	–	1022
2017 Q3	$247K	Buy	+9,579	New	+$257K	0.06%	536
2017 Q2	–	Sell	-6,755	Closed	-$201K	–	756
2017 Q1	$201K	Buy	+6,755	New	+$195K	0.03%	955

Other funds holding ACRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Trexquant Investment's ACRS Position: Q4 2023 in Review

Trexquant Investment sold out of Aclaris Therapeutics (ACRS) in Q4 2023, closing a stake of 127,851 shares — an estimated $876K sold.

Trexquant Investment first reported a position in ACRS in Q1 2017 and held it in 6 quarters. The position peaked at $876K in Q3 2023. 107 funds tracked by Wall St. Rank hold ACRS as of Q4 2023.

Trexquant Investment reported no remaining Aclaris Therapeutics position as of Q4 2023 after selling out during the quarter.
Trexquant Investment sold 127,851 Aclaris Therapeutics shares in Q4 2023, an estimated $876K.
Trexquant Investment first reported a position in Aclaris Therapeutics in Q1 2017 and held it in 6 quarters.
Trexquant Investment's Aclaris Therapeutics position peaked at $876K in Q3 2023.
107 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2023.

Based on Trexquant Investment's 13F filing for Q4 2023, filed 9 Feb 2024.